AMAG 35.03 Amag Pharmaceuticals $AMAG Hit a 52 wee
Post# of 110
Posted On: 11/19/2014 10:18:20 AM
AMAG 35.03 Amag Pharmaceuticals $AMAG Hit a 52 week high of 35.77 Closing the day 09:44 at 35.03 -0.31 -0.88% With a day low of 35.00 and a total volume of 20,837.
AMAG Recent Posts: http://investorshangout.com/AMAG-Pharmaceutic...MAG-53294/
AMAG Amag Pharmaceuticals Recent Headline News
Amarin Corporation plc (AMRN) in Focus: Stock Soars 23.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 59 mins ago
Amarin Corporation plc (AMRN) was a big mover last session, as the company saw its shares rise by over 23% on the day.
ANIP: 55.22 (-0.44), AMRN: 1.33 (+0.01), AMAG: 34.75 (-0.59), AFFX: 9.12 (-0.46)
Fate Therapeutics (FATE) Catches Eye: Stock Adds 6.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 1 hr 6 mins ago
Fate Therapeutics, Inc. (FATE) was a big mover last session, as the company saw its shares rise over 6% on the day.
AGEN: 2.94 (-0.02), FATE: 3.91 (-0.08), AMAG: 34.75 (-0.59), AFFX: 9.12 (-0.46)
Uptrend Call Working As AMAG Pharmaceuticals Stock Rises 69.1% (AMAG)
Comtex SmarTrend(R) - Tue Nov 18, 4:46PM CST
SmarTrend identified an Uptrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on August 11th, 2014 at $20.91. In approximately 3 months, AMAG Pharmaceuticals has returned 69.05% as of today's recent price of $35.34.
AMAG: 34.75 (-0.59)
Kite Pharma Gains on Positive Opinion for KTE-C19 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 4:30PM CST
Kite Pharma (KITE) received a positive opinion from the European Medicines Agency's Committee for Orphan Medicinal Products for granting orphan medicinal product status to KTE-C19.
BIIB: 304.01 (-1.55), KITE: 44.10 (+2.33), ANIP: 55.22 (-0.44), AMAG: 34.75 (-0.59)
Sunesis Pharmaceuticals (SNSS) Jumps: Stock Surges 38.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 8:25AM CST
Sunesis (SNSS) was a big mover last session, with shares surging over 38% on the day.
BIIB: 304.01 (-1.55), SNSS: 2.12 (+0.05), AMAG: 34.75 (-0.59), AFFX: 9.12 (-0.46)
Amicus Therapeutics, Inc. (FOLD) in Focus: Stock Soars 17.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 8:21AM CST
Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as the company saw its shares rise by nearly 18% on the day.
ANIP: 55.22 (-0.44), AMAG: 34.75 (-0.59), AFFX: 9.12 (-0.46), FOLD: 6.95 (+0.20)
Celldex Therapeutics, Inc. (CLDX) in Focus: Stock Soars 28.9% - Tale of the Tape
Vaishali Doshi Shah - Zacks Investment Research - Tue Nov 18, 8:18AM CST
Celldex Therapeutics, Inc. (CLDX) was a big mover last session, as the company saw its shares rise by almost 29% on the day.
ANIP: 55.22 (-0.44), CLDX: 18.40 (+0.68), AMAG: 34.75 (-0.59), AFFX: 9.12 (-0.46)
Alnylam Reports Positive Initial Phase II Data on Revusiran - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:40PM CST
Alnylam (ALNY) announced positive results of up to 98.2% knockdown of serum TTR in a phase II study on revusiran in TTR cardiac amyloidosis patients.
BIIB: 304.01 (-1.55), ALNY: 88.37 (-1.58), AMAG: 34.75 (-0.59), SNY: 48.13 (-0.23)
Bristol-Myers Squibb Reports Positive Opdivo Phase III Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:20PM CST
Bristol-Myers Squibb Company announced encouraging data from the phase III CheckMate - 066 study on immuno-oncology drug Opdivo.
AGN: 211.86 (-1.51), ACT: 265.14 (-4.46), AMAG: 34.75 (-0.59), BMY: 58.52 (-0.18)
Integra (IART) Strengthens Spinal Implant with Twin Launches - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 2:30PM CST
The latest Interbody and orthobiologic device launches are expected to drive a sequential increase in Integra Lifesciences' (IART) spine sales in the fourth quarter of 2014.
IART: 47.21 (-0.28), ANIP: 55.22 (-0.44), AMAG: 34.75 (-0.59), AFFX: 9.12 (-0.46)
Kite Pharma's Q3 Loss Narrows Y/Y, Focus on Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 9:42AM CST
Kite Pharma, Inc. (KITE) reported third-quarter 2014 loss of $0.24 per share well below the year-ago loss of $37 cents per share.
BIIB: 304.01 (-1.55), KITE: 44.10 (+2.33), ANIP: 55.22 (-0.44), AMAG: 34.75 (-0.59)
Puma Biotechnology Slumps: PBYI Tumbles 9.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 7:45AM CST
Puma Biotechnology has been witnessing a negative trend in its current year loss estimates and its share price falling for past few weeks
ANIP: 55.22 (-0.44), AMAG: 34.75 (-0.59), AFFX: 9.12 (-0.46), PBYI: 221.74 (-1.26)
Affymetrix (AFFX) Now a Strong Buy, Raised Guidance Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:13PM CST
On Nov 14, 2014, Zacks Investment Research upgraded Affymetrix Inc. (AFFX) to a Zacks Rank #1 (Strong Buy).
BIIB: 304.01 (-1.55), ANIP: 55.22 (-0.44), AMAG: 34.75 (-0.59), AFFX: 9.12 (-0.46)
AMAG Pharmaceuticals Announces Presentation at Jefferies 2014 Global Healthcare Conference in London
GlobeNewswire - Fri Nov 14, 7:00AM CST
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG), a specialty pharmaceutical company, announced today that William Heiden, AMAG's president and chief executive officer, will present at the Jefferies 2014 Global Healthcare Conference in London on Thursday, November 20, 2014 at 9:20 a.m. GMT. The session will include a company presentation followed by a question and answer session, in which the company's business and financial outlook, strategy and growth prospects will be discussed, including the acquisition of the maternal health business of Lumara Health Inc.
AMAG: 34.75 (-0.59)
AVEO Gains on Tivozanib Agreement with Ophthotech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:20PM CST
AVEO Pharmaceuticals' (AVEO) shares gained around 10.9% ever since the company announced a deal with Ophthotech (OPHT).
OPHT: 40.23 (-0.95), AVEO: 0.95 (unch), AMAG: 34.75 (-0.59)
AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:10PM CST
AstraZeneca (AZN) and Amgen (AMGN) announced encouraging results from a phase III study on brodalumab.
JNJ: 108.26 (-0.57), AZN: 74.42 (+0.44), AMGN: 161.10 (-1.14), AMAG: 34.75 (-0.59)
Intercept Pharmaceuticals Slumps: ICPT Falls 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 7:34AM CST
Intercept Pharmaceuticals has been witnessing a negative trend in its current year earnings estimate and its share price has been falling for past few days
ANIP: 55.22 (-0.44), ICPT: 159.45 (-3.05), AMAG: 34.75 (-0.59), AFFX: 9.12 (-0.46)
Alnylam Adds Hepatic Infectious Disease Drugs to Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:40PM CST
Alnylam (ALNY) expands its hepatic infectious disease pipeline with two new candidates, ALN-HDV (hepatitis delta viral) and ALN-PDL (chronic liver).
BIIB: 303.89 (-1.67), ALNY: 88.37 (-1.58), ILMN: 189.52 (-0.33), AMAG: 34.75 (-0.59)
AMAG Pharmaceuticals Completes Acquisition of Lumara Health's Maternal Health Business
GlobeNewswire - Wed Nov 12, 3:03PM CST
-- AMAG Closes $340 Million Term Loan
AMAG: 34.75 (-0.59)
AMAG Recent Posts: http://investorshangout.com/AMAG-Pharmaceutic...MAG-53294/
AMAG Amag Pharmaceuticals Recent Headline News
Amarin Corporation plc (AMRN) in Focus: Stock Soars 23.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 59 mins ago
Amarin Corporation plc (AMRN) was a big mover last session, as the company saw its shares rise by over 23% on the day.
ANIP: 55.22 (-0.44), AMRN: 1.33 (+0.01), AMAG: 34.75 (-0.59), AFFX: 9.12 (-0.46)
Fate Therapeutics (FATE) Catches Eye: Stock Adds 6.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 1 hr 6 mins ago
Fate Therapeutics, Inc. (FATE) was a big mover last session, as the company saw its shares rise over 6% on the day.
AGEN: 2.94 (-0.02), FATE: 3.91 (-0.08), AMAG: 34.75 (-0.59), AFFX: 9.12 (-0.46)
Uptrend Call Working As AMAG Pharmaceuticals Stock Rises 69.1% (AMAG)
Comtex SmarTrend(R) - Tue Nov 18, 4:46PM CST
SmarTrend identified an Uptrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on August 11th, 2014 at $20.91. In approximately 3 months, AMAG Pharmaceuticals has returned 69.05% as of today's recent price of $35.34.
AMAG: 34.75 (-0.59)
Kite Pharma Gains on Positive Opinion for KTE-C19 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 4:30PM CST
Kite Pharma (KITE) received a positive opinion from the European Medicines Agency's Committee for Orphan Medicinal Products for granting orphan medicinal product status to KTE-C19.
BIIB: 304.01 (-1.55), KITE: 44.10 (+2.33), ANIP: 55.22 (-0.44), AMAG: 34.75 (-0.59)
Sunesis Pharmaceuticals (SNSS) Jumps: Stock Surges 38.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 8:25AM CST
Sunesis (SNSS) was a big mover last session, with shares surging over 38% on the day.
BIIB: 304.01 (-1.55), SNSS: 2.12 (+0.05), AMAG: 34.75 (-0.59), AFFX: 9.12 (-0.46)
Amicus Therapeutics, Inc. (FOLD) in Focus: Stock Soars 17.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 8:21AM CST
Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as the company saw its shares rise by nearly 18% on the day.
ANIP: 55.22 (-0.44), AMAG: 34.75 (-0.59), AFFX: 9.12 (-0.46), FOLD: 6.95 (+0.20)
Celldex Therapeutics, Inc. (CLDX) in Focus: Stock Soars 28.9% - Tale of the Tape
Vaishali Doshi Shah - Zacks Investment Research - Tue Nov 18, 8:18AM CST
Celldex Therapeutics, Inc. (CLDX) was a big mover last session, as the company saw its shares rise by almost 29% on the day.
ANIP: 55.22 (-0.44), CLDX: 18.40 (+0.68), AMAG: 34.75 (-0.59), AFFX: 9.12 (-0.46)
Alnylam Reports Positive Initial Phase II Data on Revusiran - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:40PM CST
Alnylam (ALNY) announced positive results of up to 98.2% knockdown of serum TTR in a phase II study on revusiran in TTR cardiac amyloidosis patients.
BIIB: 304.01 (-1.55), ALNY: 88.37 (-1.58), AMAG: 34.75 (-0.59), SNY: 48.13 (-0.23)
Bristol-Myers Squibb Reports Positive Opdivo Phase III Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:20PM CST
Bristol-Myers Squibb Company announced encouraging data from the phase III CheckMate - 066 study on immuno-oncology drug Opdivo.
AGN: 211.86 (-1.51), ACT: 265.14 (-4.46), AMAG: 34.75 (-0.59), BMY: 58.52 (-0.18)
Integra (IART) Strengthens Spinal Implant with Twin Launches - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 2:30PM CST
The latest Interbody and orthobiologic device launches are expected to drive a sequential increase in Integra Lifesciences' (IART) spine sales in the fourth quarter of 2014.
IART: 47.21 (-0.28), ANIP: 55.22 (-0.44), AMAG: 34.75 (-0.59), AFFX: 9.12 (-0.46)
Kite Pharma's Q3 Loss Narrows Y/Y, Focus on Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 9:42AM CST
Kite Pharma, Inc. (KITE) reported third-quarter 2014 loss of $0.24 per share well below the year-ago loss of $37 cents per share.
BIIB: 304.01 (-1.55), KITE: 44.10 (+2.33), ANIP: 55.22 (-0.44), AMAG: 34.75 (-0.59)
Puma Biotechnology Slumps: PBYI Tumbles 9.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 7:45AM CST
Puma Biotechnology has been witnessing a negative trend in its current year loss estimates and its share price falling for past few weeks
ANIP: 55.22 (-0.44), AMAG: 34.75 (-0.59), AFFX: 9.12 (-0.46), PBYI: 221.74 (-1.26)
Affymetrix (AFFX) Now a Strong Buy, Raised Guidance Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:13PM CST
On Nov 14, 2014, Zacks Investment Research upgraded Affymetrix Inc. (AFFX) to a Zacks Rank #1 (Strong Buy).
BIIB: 304.01 (-1.55), ANIP: 55.22 (-0.44), AMAG: 34.75 (-0.59), AFFX: 9.12 (-0.46)
AMAG Pharmaceuticals Announces Presentation at Jefferies 2014 Global Healthcare Conference in London
GlobeNewswire - Fri Nov 14, 7:00AM CST
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG), a specialty pharmaceutical company, announced today that William Heiden, AMAG's president and chief executive officer, will present at the Jefferies 2014 Global Healthcare Conference in London on Thursday, November 20, 2014 at 9:20 a.m. GMT. The session will include a company presentation followed by a question and answer session, in which the company's business and financial outlook, strategy and growth prospects will be discussed, including the acquisition of the maternal health business of Lumara Health Inc.
AMAG: 34.75 (-0.59)
AVEO Gains on Tivozanib Agreement with Ophthotech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:20PM CST
AVEO Pharmaceuticals' (AVEO) shares gained around 10.9% ever since the company announced a deal with Ophthotech (OPHT).
OPHT: 40.23 (-0.95), AVEO: 0.95 (unch), AMAG: 34.75 (-0.59)
AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:10PM CST
AstraZeneca (AZN) and Amgen (AMGN) announced encouraging results from a phase III study on brodalumab.
JNJ: 108.26 (-0.57), AZN: 74.42 (+0.44), AMGN: 161.10 (-1.14), AMAG: 34.75 (-0.59)
Intercept Pharmaceuticals Slumps: ICPT Falls 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 7:34AM CST
Intercept Pharmaceuticals has been witnessing a negative trend in its current year earnings estimate and its share price has been falling for past few days
ANIP: 55.22 (-0.44), ICPT: 159.45 (-3.05), AMAG: 34.75 (-0.59), AFFX: 9.12 (-0.46)
Alnylam Adds Hepatic Infectious Disease Drugs to Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:40PM CST
Alnylam (ALNY) expands its hepatic infectious disease pipeline with two new candidates, ALN-HDV (hepatitis delta viral) and ALN-PDL (chronic liver).
BIIB: 303.89 (-1.67), ALNY: 88.37 (-1.58), ILMN: 189.52 (-0.33), AMAG: 34.75 (-0.59)
AMAG Pharmaceuticals Completes Acquisition of Lumara Health's Maternal Health Business
GlobeNewswire - Wed Nov 12, 3:03PM CST
-- AMAG Closes $340 Million Term Loan
AMAG: 34.75 (-0.59)
(0)
(0)Apollo Global Management Inc. (APO) Stock Research Links
Scroll down for more posts ▼